Skip Navigation
Search Menu

The Johns Hopkins Head & Neck Cancer Center
 
Print This Page
Share this page: More
 

Research and Clinical Trials

Clinical trials come from the discoveries made in basic science laboratories. By taking these investigations and discoveries, researchers and scientists can create new therapies and treatments. Below are the listings of our current clinical trials. 

Newly Diagnosed, Locally Advanced

 Trial #

 

Name of Clinical Trial

Principal Investigator

Study Coordinator

 

E3311

 

Phase II

Randomized

HPV +-

Randomized Phase II Trial of TransOral Surgical Resection (TORS) followed by low-dose or standard radiation with biomarker correlatives in resectable HPV+/ P16+ locally advanced oropharynx cancer

Wayne Kock, MD

 

Tracy Weikel, RN

410-955-4044

 

J15117

 

 

Phase I/II

 

Phase I/ II  Study of Nivolumab in Subjects with Virus-Positive and Virus-Negative Solid Tumors.

William Sharfman, MD

Trish Brothers, RN

ACRIN

6685

 

 

A Multi-Center Trial of FDG-PET/CT staging of head and neck cancer and its impact on the N0 neck surgical treatment 

Lilja

Solnes, MD 

 

Charles Marcus

410-502-7634

J14191Feasibility StudyA feasibility study of the Vibrant ™ Smartphone App for Head and Neck Cancer Patients: Supporting pain management of radiation-induced mucositis .

Harry

Quon, MD
DiPasquale 


Recurrent and/or Metastatic

Trial #

 

Name of Clinical Trial

Principal Investigator

Study Coordinator

1st Line    

J15183

Phase II

Phase II Trial of reirradiation combined with open label

MK-3475 ( Pembrolizumab) in patients with locoreginal inoperable recurrence or second primary squamous cell carcinoma of the head and neck

Ana Kiess, MD 

 
J15207

Phase III

Randomized
Phase III Randomized ,Open-Label, Multi-Center, Global Study of MEDI4736 alone or in combination with Tremelimumab vs standard of care in the treatment of first-line recurrent or metastatic squamous cell head and neck cancer patients 

Hyu Kang, MD

Pawla Wenga

410-502-3820

2nd/3rd Line    
J1591Phase IPhase I Study to evaluate the safety, tolerability, and efficacy of MEDI4736 in combination with Tremelimumab in subjects with recurrent or metastatic squamous cell carcinoma of the head and neck

Hyu Kang, MD

Pawla Wenga

410-502-3820

J1282Phase IPhase 1 Study to evaluate the safety, tolerability, and efficacy of Lirilumab administered in combination with Nivolumab in advanced refractory solid tumors 

William Sharfman, MD 

Alice Pons, RN

J15117Phase I/IINon-comparative, two-cohort, single-arm, open-label study of Nivolumab in subjects with virus-positive and virus-negative solid tumors

William Sharfman, MD 

Trish
J1551Phase I/IIPhase I/II study of MEDI4736 alone or in combination with ADXS11-001 in recurrent persistent or metastatic cervical or HPV positive SCC of the head and neck 

Hyu Kang, MD

Nancy Tsottles,RN 


HPV Epidemiology Study

Trial #

 

Name of Clinical Trial

Principal Investigator

Study Coordinator

 PROVE
J1366

 

Papillomavirus role in oral cancer viral etiology ( PROVE)

Amber D'Souza, MD
Carol Fakhry, MD

Tanya Troy, MPH

443-287-8754

 

Quality of Life Outcome Study

Trial #

Name of Clinical Trial

Principal Investigator

Research Nurse

 J13140Oropharynx anatomic imaging with ultrasound
Carol Fakhry, MD

 

ADENOID CYSTIC CARCINOMA 

J1530

Phase I- Phase I Study of the safety, pharmacokinetics, and pharmacodynamics of PLX7486-TsOH as a single agent and in combination with Gemcitabine and Paclitaxel in patients with advanced solid tumors

Hyu Kang, MD

Pawla Wenga

410-502-3820

NASOPHARYNGEAL CARCINOMA 

J1102A Phase I Trial of Oral5-Azacitidine in combination with Romidepsin in advanced solid tumors with an expansion cohort in virally mediated cancers and liopsarcoma

Nilo Azad, MD

Fischer

Detailed descriptions of these trials are available at  www.clinicaltrials.gov

 

 
 

Read Our Blogs
Cancer Matters: timely topics
Our Cancer: for caregivers

 

Department of Otolaryngology
Head and Neck Surgery

Learn more about our services

Meet our team

Meet our director

 

NCI CCC